Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

LiDCO Extends Collaboration With BD

16 Apr 2009 07:00

RNS Number : 6366Q
LiDCO Group Plc
15 April 2009
 



Press Release 

16 April 2009

LiDCO Group Plc

("LiDCO" or "the Company")

LiDCO extends collaboration with BD

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today has extended its exclusive collaboration with BD (Becton, Dickinson and Company)a leading global medical technology company dedicated to helping all people live healthy lives (see www.bd.com).

In June 2007, LiDCO signed an exclusive UK marketing collaboration with Becton, Dickinson U.K. LimitedLiDCO today announces the expansion of this exclusive collaboration with BD. Under the amended and restated terms of the agreement, LiDCO and BD will extend their exclusive marketing collaboration to include additional territories. The collaboration provides that BD Medical - Medical Surgical Systems regional sales teams will provide sales and marketing support for LiDCO products in territories additional to the UK. This marketing collaboration will result in an enhanced product offering for BD's customers as well as superior sales coverage for both LiDCO and LiDCO's network of distributors. 

In a separate agreement, LiDCO have entered an exclusive distribution and sales relationship for the LiDCOrapid Monitor with BD in Japan. This relationship will result in an enhanced product offering for BD customers, as well as improved access to LiDCO's technology by Japanese clinicians and patients. 

Dr Terry O'Brien, Chief Executive of LiDCO, commenting on the agreements stated: "This licensing arrangement in Japan and expansion of our marketing collaboration with a major corporation of the stature of BD further enhances our capabilities to provide our acute care customers with the best possible products and services to improve outcomes and reduce complications such as infections. We are very pleased to share a commitment with BD towards expanding access to innovative technologies that improve outcomes in the critically ill." 

Hideyuki Ashikaga, President, BD in Japan stated:

"BD designs and markets innovative products that address significant healthcare problems and deliver demonstrably higher benefits to patients, healthcare workers and researchers. Collaborating with LiDCO, an innovative company in an important healthcare market, will reinforce our capabilities to serve that market, in line with our corporate purpose of 'Helping all people live healthy lives'".

- ENDS -

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com

FinnCap

Geoff Nash/ Stephen Norcross/

Marc Young 

+44 (0)20 7600 1658

www.finncap.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves 

+44 (0)20 7398 7728

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIAMFTMMJBBML
Date   Source Headline
12th Feb 20207:00 amRNSHolding(s) in Company
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
3rd Feb 20207:00 amRNSBlock Listing Review
18th Nov 20199:32 amRNSDirector/PDMR Shareholding
7th Nov 201910:30 amRNSLiDCO to present at Mello London, 2019
5th Nov 20197:00 amRNSLatest monitor launched in China
16th Oct 20197:00 amRNSDirector/PDMR Shareholding
15th Oct 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSCapital Markets Day & technology agreement
20th Aug 20197:00 amRNSCapital Markets Day
20th Aug 20197:00 amRNSTrading update & Notice of results
15th Aug 20197:00 amRNSAppointment of Non-Executive Director
1st Aug 20197:00 amRNSBlock Listing Review
16th Jul 20197:00 amRNSRegulatory approval in China
16th May 201910:30 amRNSResult of AGM
16th May 20197:00 amRNSAGM Statement
23rd Apr 20197:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
17th Apr 20197:00 amRNSRegulatory approval in South Korea
16th Apr 20197:00 amRNSAward of share options/director dealing
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
1st Apr 20195:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSDirector/PDMR Shareholding
26th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSMaster distribution agreement for Latin America
8th Mar 20197:00 amRNSHUP progress update
5th Mar 20197:00 amRNSDirectorate Change
20th Feb 20195:00 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSPre-Close Trading Update and Notice of Results
1st Feb 20197:00 amRNSBlock Listing Review
17th Dec 20187:00 amRNSTrading update and notice of results
12th Oct 201811:20 amRNSHolding(s) in Company
9th Oct 20187:01 amRNSHalf-year Report
9th Oct 20187:00 amRNSUK distribution agreement with Shenzhen Antmed
24th Sep 20187:00 amRNSDirectorate Change
20th Aug 20182:58 pmRNSHolding(s) in Company
20th Aug 20187:00 amRNSTrading update & Notice of results
1st Aug 20188:41 amRNSBlock listing Review
19th Jul 20187:00 amRNSUK distribution agreement with Maicuff Technology
29th Jun 20187:11 amRNSAward of share options/director dealing
17th May 201810:36 amRNSResult of AGM
17th May 20187:00 amRNSAGM Statement
16th May 20187:00 amRNSCapital Markets Day & US progress update
24th Apr 20187:00 amRNSCapital Markets Day
24th Apr 20187:00 amRNSPosting of Annual Report & Accounts& Notice of AGM
10th Apr 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSEnd of third party UK Distribution agreement
22nd Feb 20187:00 amRNSAppointment of French distributor
15th Feb 20187:01 amRNSTrading update and notice of results
15th Feb 20187:00 amRNSSignificant US & UK HUP wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.